Nasopharyngeal Cancer – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Nasopharyngeal Cancer – Pipeline Review, H2 2018’, provides an overview of the Nasopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer

– The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

Ambrx Inc

arGEN-X BV

Ascentage Pharma Group Corp Ltd

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

BeiGene Ltd

Biomics Biotechnologies Co Ltd

Bristol-Myers Squibb Co

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

F. Hoffmann-La Roche Ltd

FLX Bio Inc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Molecular Partners AG

Neonc Technologies Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford Vacmedix UK Ltd

Soricimed Biopharma Inc

Systimmune Inc

Tessa Therapeutics Pte Ltd

Vectorite Biomedical Inc

Viracta Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Nasopharyngeal Cancer Overview 6

Nasopharyngeal Cancer Therapeutics Development 7

Nasopharyngeal Cancer Therapeutics Assessment 18

Nasopharyngeal Cancer Companies Involved in Therapeutics Development 28

Nasopharyngeal Cancer Drug Profiles 42

Nasopharyngeal Cancer Dormant Projects 405

Nasopharyngeal Cancer Discontinued Products 407

Nasopharyngeal Cancer Product Development Milestones 408

Appendix 416

List of Tables

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Nasopharyngeal Cancer Pipeline by Advenchen Laboratories LLC, H2 2018

Nasopharyngeal Cancer Pipeline by Ambrx Inc, H2 2018

Nasopharyngeal Cancer Pipeline by arGEN-X BV, H2 2018

Nasopharyngeal Cancer Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Atara Biotherapeutics Inc, H2 2018

Nasopharyngeal Cancer Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Nasopharyngeal Cancer Pipeline by BeiGene Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Biomics Biotechnologies Co Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Bristol-Myers Squibb Co, H2 2018

Nasopharyngeal Cancer Pipeline by CBT Pharmaceuticals Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Celgene Corp, H2 2018

Nasopharyngeal Cancer Pipeline by Cell Medica Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by FLX Bio Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Incyte Corp, H2 2018

Nasopharyngeal Cancer Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by MedImmune LLC, H2 2018

Nasopharyngeal Cancer Pipeline by Merck & Co Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Merck KGaA, H2 2018

Nasopharyngeal Cancer Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Molecular Partners AG, H2 2018

Nasopharyngeal Cancer Pipeline by Neonc Technologies Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Novartis AG, H2 2018

Nasopharyngeal Cancer Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Otsuka Holdings Co Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Oxford Vacmedix UK Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Soricimed Biopharma Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Systimmune Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Tessa Therapeutics Pte Ltd, H2 2018

Nasopharyngeal Cancer Pipeline by Vectorite Biomedical Inc, H2 2018

Nasopharyngeal Cancer Pipeline by Viracta Therapeutics Inc, H2 2018

Nasopharyngeal Cancer Dormant Projects, H2 2018

Nasopharyngeal Cancer Dormant Projects, H2 2018 (Contd..1), H2 2018

Nasopharyngeal Cancer Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports